
Evidence Summary: Lymphoedema: Objective assessment using volumetry

Nov 2014

Author

Wound Healing and Management Node Group — Emily Haesler

QUESTION

What is the best available evidence on using volumetry to assess lymphoedema?

BACKGROUND

Lymphoedema is a form of chronic, progressive oedema in which there is significant, persistent swelling of a limb or other body region due to excess and abnormal accumulation of protein-rich fluid in body tissues¹⁻⁵. The lymphatic system is unable to manage the volume of accumulated fluid⁴.

Lymphoedema occurs due to primary, secondary or mixed causes. Primary causes are described as congenital (for example, an inherited disorder such as Milroy's disease), praecox (onset at puberty, for example, Meig's disease) or tarda (sudden onset, no apparent cause)⁶⁻⁸. Secondary causes arise from direct damage or trauma to the lymphatic system such as injury surgery or radiotherapy (usually related to treatment of breast cancer), or parasitic invasion⁷⁻⁹. Lymphatic filariasis (also called elephantitis) is a cause of secondary lymphoedema in endemic areas primarily in Africa and Asia. Lymphatic filariasis is a parasitic (roundworm) infection that is spread by mosquitoes and causes damage to the lymphatic system that may result in lymphoedema. Infection generally occurs in childhood. Management focuses on large-scale treatment programs to reduce disease spread^{5,10}. Mixed lymphoedema describes lymphoedema arising from decompensation or failure of the lymphatic system associated with other disease or conditions, including but not limited to obesity, immobility, venous disease or lipoedema^{7,8,11}.

Without management, lymphoedema may lead to:^{4,12}

- progressive swelling
- superficial tissue changes — increasing adiposity and fibrosis
- physical and functional limitations
- increased risk of chronic infection
- lymphorrhoea (leaking of lymph fluid)
- pain and discomfort
- reduced ability to undertake activities of daily living (ADLs).

Comprehensive assessment of lymphoedema includes objective measures of volume/size, and subjective assessment of signs and symptoms, including their impact on the patient¹³. In patients with mixed lymphoedema, it is also important to assess factors associated with the underlying disease or condition (not addressed in this evidence summary).

This evidence summary presents evidence related to the reliability and validity of one objective measurement used to assess lymphoedema: volumetry.

Volumetry is the measure of limb volume, the gold standard for which is water displacement¹⁴. Limb volume measurements may be reported as a volume, or as an estimated volume that is calculated from limb circumference measurements using a standardised formula. The second option is less reliable as it assumes a consistent cylindrical circumference, which is not usually reflective of the oedematous limb¹; however, it may be more practical in clinical settings where water displacement is inconvenient to perform¹⁴.

CLINICAL BOTTOM LINE

Performing volumetry

Assessment is performed using a volumeter, in which the patient's arm is submerged in water and the difference in water level before and during arm placement is made⁴, or the displaced water is measured using a scale or container¹⁵ (Level 1.b evidence). Various techniques are used.

- The patient may be standing or seated, and the limb may be submerged to the point of the axilla, or to a point at 65% of the distance between the cubital fossa and the acromion¹⁵ (Level 1.b evidence).
- The water must be stabilised before a measurement of displaced water is taken, with care to ensure the patient is as still as possible¹⁵ (Level 1.b evidence).
- For all measures of limb size and/or volume, comparison should be made with:^{13,16}
 - a pre-condition measurement of the affected limb (where available) to determine severity of lymphoedema;
 - the unaffected limb to determine severity; and
 - the affected limb over time to objectively assess the effectiveness of the management plan.

Reliability of volumetry

- In one validation study involving 14 patients with breast cancer-associated lymphoedema, the reliability of water displacement measures was investigated. Both intrarater (two measurements) and interrater (two raters) reliability were excellent (ICC=0.999, 95% CI 0.997 to 1.00, p<0.05 for both comparisons). Standard error of measurement was 1.1% for both intrarater and interrater reliabilities¹⁷ (Level 3.e evidence).

- In one validation study (n=23 women, mostly breast cancer surgery) the water displacement method was found to be a valid measure of lymphoedema in a comparison with (computed tomography) scan and magnetic resonance imaging (MRI). Arm volume measured by water displacement was significantly correlated (r=0.904) with CT scan measures of total cross-section area (CSA) and to CSA of both subcutaneous tissue (R=0.867, p<0.001) and muscle tissue (R=0.725, p<0.001)¹⁸ (Level 3.c evidence).
- Published opinion on diagnostic cut-off points recommend using a limb volume difference of 200mL or a 10% difference; however, there are currently no standardised cut-offs^{1,4} (Level 5.c evidence).

Limitations of volumetry

- The measurement method is unable to distinguish between muscle, bone, fat and fluid¹⁵.
- Insufficient presence of lymphoedema results in a detectable change in water volume⁴. The minimal detectable change is reported to be above 150 mL¹⁵.
- Impaired skin integrity in the limb precludes use of this measurement method^{4,19}.
- Water overflow has previously been an issue, but modern options reduce this limitation^{1,17}.
- Infection control is required between uses of the measurement device, particularly between patients^{1,20}.
- Provides no data on localised oedema or shape of the extremity¹.
- Water temperature must be kept within a specific range¹⁹.

CHARACTERISTICS OF THE EVIDENCE

This evidence summary is based on a structured literature and database search combining search terms that describe lymphoedema and assessment. The evidence in this summary comes from:

- Systematic reviews of studies of various design^{2,15} (Level 1.b evidence).
- Cohort studies with control groups^{16,18,20} (Level 3.c evidence).
- Observational studies with no control group^{9,13,17,19} (Level 3.e evidence).
- Case series report¹¹ (Level 4.c evidence).
- Expert consensus^{5,7} (Level 5.b evidence).
- Expert opinion^{1,3,4,6,8,10,12,14} (Level 5.c evidence).

BEST PRACTICE RECOMMENDATIONS

Volumetry is a reliable and valid strategy for assessing the presence and degree of lymphoedema in adults. (Grade B)

Related evidence summaries

JB1 10912 Identification of people at risk of venous leg ulcers

- JB1 11559 Lymphedema: classification
- JB1 11564 Lymphedema: objective assessment using bioimpedance spectroscopy
- JB1 11562 Lymphedema: objective assessment using perometry
- JB1 11560 Lymphedema: subjective assessment
- JB1 11870 Lymphedema: objective assessment using tonometry

REFERENCES

1. Armer J. The problem of post-breast cancer lymphedema: Impact and measurement issues. *Cancer Invest* 2005; 1:76–83. (Level 5.c evidence).
2. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. *Lancet Oncol* 2013; 14:500–15. (Level 1.b evidence).
3. Todd M. Chronic oedema: impact and management. *Br J Nurs* 2013; 22(11):623–27. (Level 5.c evidence).
4. Balci F, DeGore L, Soran A. Breast cancer-related lymphedema in elderly patients. *Top Geriatr Rehabil* 2012; 28(4):242–53. (Level 5.c evidence).
5. Lymphoedema Framework. Best Practice for the Management of Lymphoedema. London: MEP Ltd, 2006. (Level 5.b evidence).
6. Mayo Clinic staff. 2014. Diseases and Conditions: Lymphoedema. Available from: <http://www.mayoclinic.org/diseases-conditions/lymphedema/basics/causes/con-20025603>. [Accessed 2014 May] (Level 5.c evidence).
7. International Society Of Lymphology. The Diagnosis and Treatment of Peripheral Lymphedema. Consensus Document of the International Society Of Lymphology. *Lymphology* 2013; 46:1–11. (Level 5.b evidence).
8. General Practice Divisions of Victoria. unknown. Lymphoedema: Guide for diagnosis and management in general practice. Available from: http://www.gpv.org.au/files/downloadable_files/Programs/Lymphoedema/Lymphoedema_GP_%20Info_%20guide.pdf. [Accessed 2014 June] (Level 5.c evidence).
9. Kim L, Jeong J-Y, Sung I-Y, Jeong S-Y, Do J-H, Kim H-J. Prediction of treatment outcome with bioimpedance measurements in breast cancer-related lymphedema patients. *Ann Rehabil Med* 2011; 35:687–93. (Level 3.e evidence).
10. World Health Organization. Lymphatic filariasis: Fact Sheet No 102. www.who.int/mediacentre/factsheets/fs102/en/: World Health Organization,2014. (level 5.c evidence).
11. Greene AK, Grant FD, Slavin SA. Lower-extremity lymphedema and elevated body-mass index. *N Engl J Med* 2012; 366(22):2136–7. (Level 4.c evidence).
12. Renshaw M. Lymphorrhoea: 'leaky legs' are not just the nurse's problem. *Br J Community Nurs* 2007; 12(2):S18–21. (Level 5.c evidence).
13. Armer J, Radina M, Porock D, Culbertson S. Predicting breast cancer-related lymphedema using self-reported symptoms. *Nurs Res*, 2003; 52(6):370–9. (Level 3.e evidence).
14. Bernas M. Assessment and risk reduction in lymphoedema. *Semin Oncol Nurs*, 2013;29(1):12–9. (Level 5.c evidence).

15. Perdomo M, Levenhagen K, Davies C, Ryans K. Assessment measures of secondary lymphedema in breast cancer survivors. *Rehabil Oncol* 2014; 32(1):22–35. (Level 1.b evidence).


16. Czerniec S, Ward L, Refshauge K, Beith J, Lee M, York S, Kilbreath S. Assessment of breast cancer-related arm lymphedema — Comparison of physical measurement methods and self-report. *Cancer Invest* 2010; 28:54–62. (Level 3.c evidence).

17. Chen Y-W, Tsai H-J, Hung H-C, Tsauo J-Y. Reliability study of measurements for lymphedema in breast cancer patients. *Am J Phys Med Rehabil* 2008; 87(1):33–8. (Level 3.e evidence).

18. Sagen A, Kåresen R, Skaane P, Risberg M. Validity for the simplified water displacement instrument to measure arm lymphedema as a result of breast cancer surgery. *Arch Phys Med Rehabil* 2009; 90:803–9. (Level 3.c evidence).

19. Borthwick Y, Paul L, Sneddon M, Mcalpine L, Miller C. Reliability and validity of the figure-of-eight method of measuring hand size in patients with breast cancer-related lymphoedema. *Eur J Cancer Care* 2013; 22:196–201. (Level 3.e evidence).

20. Taylor R, Jayasinghe U, Koelmeyer L, Ung O, Boyages J. Reliability and validity of arm volume measurements for assessment of lymphedema. *Phys Ther* 2006; 86:205–14. (Level 3.c evidence).



- Count on AQUACEL® Foam dressings to protect against skin breakdown caused by excess moisture or shear force.*†
- AQUACEL® Foam dressing demonstrated significantly lower shear force than Mepilex™ Border dressing ($p < 0.001$)*.†
- Small and large sacral sizes available to help meet your clinical care needs

AQUACEL® Foam

Protection where it counts...

New Large Sacral Size Available!

In vitro shear force measured under dressing†

Weight applied dynamically across dressing surface (g)	AQUACEL® Foam Shear Force (N)	Mepilex™ Border Shear Force (N)
1000	~0.2	~0.4
1500	~0.3	~0.5
2000	~0.4	~0.6
2500	~0.5	~0.7
3000	~0.6	~0.8
3500	~0.7	~0.9

* As demonstrated *in vitro*
† AQUACEL® Foam dressing may be used in a comprehensive protocol of care to protect against skin breakdown.

Reference: 1. Comparative Assessment of *in vitro* Shear Force Reduction through AQUACEL® Foam and Mepilex™ Border Dressings. WHR13783 TA290. Data on File. ConvaTec Inc.

TM indicates trademarks of ConvaTec Inc. AQUACEL, the AQUACEL logo, ConvaTec, the ConvaTec logo, Hydrofiber and the Hydrofiber logo are registered trademarks in the U.S. and Tried, True, Trusted, is a trademark of ConvaTec Inc. All other trademarks are the property of their respective owners.

© 2015 ConvaTec Inc. AP-014135-US

ConvaTec (Australia) Pty Limited. ABN 70 131 232 570. PO Box 63, Mulgrave, VIC 3170. Phone: (03) 9239 2700. Facsimile: (03) 9239 2742. Customer Support Freecall: 1800 339 412. www.convatec.com.au February 2015 ADW046

AQUACEL Dressings
TRIED. TRUE. TRUSTED.

Australia
1800 339 412

New Zealand
0800 441 763
www.convatec.com